Patent Application CN 113365623 A: Anti-androgen for Treating Metastatic Castration-Sensitive Prostate Cancer

The present invention provides an anti-androgen for treating metastatic castration-sensitive prostate cancer, which includes, but is not limited to 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.


Patent Application CN 113365623 A: Anti-androgen for Treating Metastatic Castration-Sensitive Prostate Cancer - cover page
Category
Drugs
Document type
Other
Language
Chinese
Pages
88
File format
PDF
File size
5.5 MB
Published
16 November, 2023
Updated
16 November, 2023
MD5 checksum
3BC98B26E330752223FD4E7A968CF9F2

About this manual

This document is a Chinese invention patent application published on 2021-09-07 as CN 113365623 A. It was filed by Aragon Pharmaceuticals (阿拉和贡药品公司) on 2020-01-30 and claims priority to several US provisional applications; the PCT application was published as WO2020/157699.

The claims describe methods for treating metastatic castration-sensitive prostate cancer in male humans with anti-androgens, including apalutamide, alone or with androgen deprivation therapy. They also mention oral dosing ranges, combination with GnRH agonists/antagonists or bilateral orchiectomy, and restrictions on co-administration with certain drugs. This manual is written in Chinese.

What's inside

  • Bibliographic data
  • Applicant
  • Priority data
  • PCT application data
  • Abstract
  • Claims

Frequently asked questions

What medical condition does this patent application concern?

It concerns methods for treating metastatic castration-sensitive prostate cancer in male humans.

What oral dose of apalutamide is mentioned?

The claims mention oral administration at about 240 mg per day.

Can the anti-androgen be combined with androgen deprivation therapy?

Yes, the claims describe combination with androgen deprivation therapy.

Download PDF (5.5 MB)

Also Manuals